← Leaderboards
Kottil Rammohan
Ohio State University
$924,380
Attributed
$924,380
Total exposure
18
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $105.7K · FY2007–08$200K$150K$100K$50K$0
'07
'08
Funding mix
By agency
NIH$924,380 · 18
By mechanism
M01$924,380 · 18
Top collaborators
No co-investigators on record.
Most similar at Ohio State University
Same institution · by research overlap
- Kimerly Ann Powell$868,726
- Amy E Lovett-Racke$7,052,190
- Gregory A Otterson$1,550,120
- William E. Carson$27,905,247
- Dorcas J Lynn$346
Others in their field
Top investigators on “Funding”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,479,940,681
- Leonard Freedman · Leidos Biomedical Research, Inc.$968,195,877
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Jeffrey P Krischer · University Of South Florida$358,470,093
Research focus
FundingSourceUnited States National Institutes Of HealthInstitutionResourcesComputer Retrieval Of Information On Scientific Projects DatabaseResearch PersonnelGrantSafetyRelapseHuman SubjectClinical ResearchMultiple SclerosisInterferon BetaDailyClinical TrialsDoseHuman Therapy EvaluationNervous System Disorder ChemotherapyDouble-Blind MethodRandomizedPlacebosTreatment DurationWeek
Grant awards (24)
CLINICAL TRIAL: INTERFERON BETA-LA AND GLATIRAMER ACETATE TO EITHER AGENT ALONE$41,231
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: GLATIRAMER ACETATE IN RRMS$24,600
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: RITUXIMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS$14,206
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: TREATMENT OF INADEQUATE CD4+ LYMPHOCYTE RECOVERY IN RRMS$7,969
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL CLADRIBINE$7,276
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: SAFETY TOLERABLILITY, AND EFFICACY OF BETASERON?/BETAFERON$5,890
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: SAFETY AND TOLERABILITY OF BETASERON IN PATIENTS WITH RRMS$2,425
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: SAFETY, TOLERABILITY, AND EFFECTS OF TWO DOSES OF CDP323 IN MS$2,079
M01 · FY2008 · RR · contact PI
RITUXIMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS$41,296
M01 · FY2007 · RR · contact PI
INTERFERON BETA-LA AND GLATIRAMER ACETATE TO EITHER AGENT ALONE$35,133
M01 · FY2007 · RR · contact PI
REBIF WITH COPAXONE ADMINISTERED TO RELAPSING REMITTING MULTIPLE SCLEROSIS PTS$8,630
M01 · FY2007 · RR · contact PI
SAFETY AND TOLERABILITY OF BETASERON IN PATIENTS WITH RRMS$3,082
M01 · FY2007 · RR · contact PI
GLATIRAMER ACETATE IN RRMS$2,465
M01 · FY2007 · RR · contact PI
STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL CLADRIBINE$616
M01 · FY2007 · RR · contact PI
SAFETY AND EFFICACY OF TWO DOSES OF BETASERON$193,916
M01 · FY2001 · RR
EVALUATE EFFICACY OF AVONEX &SECONDARY MULTIPLE SCLEROSIS$193,916
M01 · FY2001 · RR
AVONEX IN TREATING HIGH DEVELOPMENT OF MULTIPLE SCLEROSIS$193,916
M01 · FY2001 · RR
EVALUATE EFFICACY OF AVONEX &SECONDARY MULTIPLE SCLEROSIS$48,578
M01 · FY2000 · RR
SAFETY AND EFFICACY OF TWO DOSES OF BETASERON$48,578
M01 · FY2000 · RR
AVONEX IN TREATING HIGH DEVELOPMENT OF MULTIPLE SCLEROSIS$48,578
M01 · FY2000 · RR
AVONEX IN TREATING HIGH DEVELOPMENT OF MULTIPLE SCLEROSIS$0
M01 · FY2000 · RR
EVALUATE EFFICACY OF AVONEX &SECONDARY MULTIPLE SCLEROSIS$0
M01 · FY2000 · RR
TREATMENT OF FATIGUE IN MULTIPLE SCLEROSIS WITH PROVIGIL (MODAFINIL)$0
M01 · FY2000 · RR
TREATMENT OF FATIGUE IN MULTIPLE SCLEROSIS WITH PROVIGIL (MODAFINIL)$0
M01 · FY2000 · RR